# í†µí•© ë°ì´í„° ì§„ë‹¨ ê²°ê³¼

**ìƒì„± ì‹œê°„**: 2025-12-17 10:59:28

---

```
================================================================================
1. NULL/ë¹ˆ ê°’ ë¶„ì„ (Study ë‹¨ìœ„)
================================================================================

ğŸ“Š ì „ì²´ Studies: 3,867ê±´
  âŒ measure_raw ê²°ì¸¡ Study: 0ê±´ (0.0%)
  âŒ description_raw ê²°ì¸¡ Study: 673ê±´ (17.4%)
  âŒ time_frame_raw ê²°ì¸¡ Study: 109ê±´ (2.8%)

âœ… ìœ íš¨ ë°ì´í„° Study ìˆ˜:
  âœ“ measure_raw ìœ íš¨: 3,867ê±´ (100.0%)
  âœ“ description_raw ìœ íš¨: 3,194ê±´ (82.6%)
  âœ“ time_frame_raw ìœ íš¨: 3,758ê±´ (97.2%)

ğŸ“‹ íƒ€ì…ë³„ í†µê³„ (Study ë‹¨ìœ„):

  PRIMARY: 3,867ê±´
    âŒ measure ê²°ì¸¡ Study: 0ê±´ (0.0%)
    âŒ timeFrame ê²°ì¸¡ Study: 111ê±´ (2.9%)

  SECONDARY: 2,906ê±´
    âŒ measure ê²°ì¸¡ Study: 0ê±´ (0.0%)
    âŒ timeFrame ê²°ì¸¡ Study: 92ê±´ (3.2%)

================================================================================
ğŸ“‹ ì •ê·œí™” ë£° ì„¤ëª…
================================================================================

ğŸ”§ 1ì°¨ ì •ê·œí™” ë£° (Phase 1):

1. í…ìŠ¤íŠ¸ í´ë¦¬ë‹:
   â€¢ ê³µë°± ì •ë¦¬ (ì—°ì† ê³µë°± â†’ ë‹¨ì¼ ê³µë°±)
   â€¢ ì˜¤íƒ€ êµì • (extention â†’ extension ë“±)

2. timeFrame íŒŒì‹±:
   âœ… íŒŒì‹± ê°€ëŠ¥í•œ íŒ¨í„´:
      - Baseline í¬í•¨: "Baseline, Week 16" â†’ change_from_baseline_flag = TRUE
      - At Day/Week/Month N: "At Day 1", "At Week 14", "At Month 12" â†’ N, day/week/month
      - Day/Month/Week N ë‹¨ë…: "Day 1", "Month 3", "Week 12" â†’ N, day/month/week
      - Day N to/through M: "Day 1 to day 30", "Day 1 through 7" â†’ ì‹œì‘ì¼, ì¢…ë£Œì¼ ì¶”ì¶œ
      - For N Months/Weeks/Days: "For 10 Months" â†’ 10, month
      - At Months N and M: "At Months 6 and 12" â†’ ë³µìˆ˜ ì‹œì  ì¶”ì¶œ
      - í…ìŠ¤íŠ¸ ìˆ«ì+ë‹¨ìœ„: "Two years", "eight weeks" â†’ 2, year / 8, week
      - ìˆ«ì+ë‹¨ìœ„: "26 weeks" â†’ 26, weeks
      - Year N: "Year 3.5" â†’ 3.5, year
      - Up to: "up to 72 hours" â†’ 72, hour
      - Through: "through study completion, an average of 1 year" â†’ 1, year
   
   âŒ íŒŒì‹± ì–´ë ¤ìš´ íŒ¨í„´:
      - "% of exact responses" (ì‘ë‹µë¥ )
      - "The time to respond" (ì‹œê°„/ì†ë„)
      - "0 Hour (pre-dose) on Day 1" (ë³µì¡í•œ ì‹œì  í‘œí˜„)
      - "3 Days in each of the 4 dosing session" (ë³µì¡í•œ ì¡°ê±´ë¶€ í‘œí˜„)
      - ê¸°íƒ€ ë¹„í‘œì¤€ í‘œí˜„

3. change_from_baseline í”Œë˜ê·¸:
   â€¢ descriptionì—ì„œ "change from baseline" íŒ¨í„´ ê²€ìƒ‰
   â€¢ ë°œê²¬ ì‹œ í”Œë˜ê·¸ = TRUE

4. Phase íƒœê¹…:
   â€¢ double-blind, extension, follow-up ë“± í‚¤ì›Œë“œ ì¶”ì¶œ


================================================================================
ğŸ“Š ê¸°ê´€/ë‹´ë‹¹ì ì „ì²´ í†µê³„
================================================================================

ğŸ¢ LEAD_SPONSOR (ê¸°ê´€) í†µê³„:
  ì´ ê¸°ê´€ ìˆ˜: 1,317ê°œ
  ì´ Study ìˆ˜: 3,987ê±´
  ì´ ë ˆì½”ë“œ ìˆ˜: 3,987ê±´

  Study ë¶„í¬:
    í‰ê· : 3.0ê±´/ê¸°ê´€
    ìµœì†Œ: 1ê±´
    ìµœëŒ€: 62ê±´

ğŸ‘¤ OFFICIAL (ë‹´ë‹¹ì) í†µê³„:
  ì´ ë‹´ë‹¹ì ìˆ˜: 2,808ëª…
  ì´ Study ìˆ˜: 3,025ê±´
  ì´ ë ˆì½”ë“œ ìˆ˜: 3,746ê±´

  Study ë¶„í¬:
    í‰ê· : 1.3ê±´/ë‹´ë‹¹ì
    ìµœì†Œ: 1ê±´
    ìµœëŒ€: 65ê±´

================================================================================
2. timeFrame íŒ¨í„´ ë¶„ì„
================================================================================

ğŸ“Š ì´ timeFrame ë°ì´í„°: 25,257ê±´

ğŸ“ˆ íŒ¨í„´ ë¶„ë¥˜ ê²°ê³¼:
  â€¢ Baseline í¬í•¨ (change_from_baseline): 9,469ê±´ (37.5%)
  â€¢ ê¸°ê°„ íŒ¨í„´ (At Day/Week/Month N): 265ê±´ (1.0%)
  â€¢ ê¸°ê°„ íŒ¨í„´ (Day/Month/Week N ë‹¨ë…): 3,548ê±´ (14.0%)
  â€¢ ê¸°ê°„ íŒ¨í„´ (Day N to/through M): 0ê±´ (0.0%)
  â€¢ ê¸°ê°„ íŒ¨í„´ (For N Months/Weeks/Days): 62ê±´ (0.2%)
  â€¢ ê¸°ê°„ íŒ¨í„´ (At Months N and M): 0ê±´ (0.0%)
  â€¢ ê¸°ê°„ íŒ¨í„´ (í…ìŠ¤íŠ¸ ìˆ«ì+ë‹¨ìœ„): 684ê±´ (2.7%)
  â€¢ ê¸°ê°„ íŒ¨í„´ (ìˆ«ì+ë‹¨ìœ„): 8,543ê±´ (33.8%)
  â€¢ ê¸°ê°„ íŒ¨í„´ (Year N): 30ê±´ (0.1%)
  â€¢ ê¸°ê°„ íŒ¨í„´ (Up to): 1,360ê±´ (5.4%)
  â€¢ ê¸°ê°„ íŒ¨í„´ (Through): 302ê±´ (1.2%)
  â€¢ ì‘ë‹µë¥ /ë¹„ìœ¨: 1ê±´ (0.0%)
  â€¢ ì‹œê°„/ì†ë„: 0ê±´ (0.0%)
  â€¢ ê¸°íƒ€/ë¶ˆëª…í™•: 993ê±´ (3.9%)

ğŸ¯ íŒŒì‹± ê°€ëŠ¥ì„± ìš”ì•½:
  âœ… íŒŒì‹± ê°€ëŠ¥ (ê¸°ê°„ íŒ¨í„´ + Baseline í¬í•¨): 24,263ê±´ (96.1%)
  âŒ íŒŒì‹± ì–´ë ¤ì›€ (ê¸°íƒ€/ë¶ˆëª…í™•): 994ê±´ (3.9%)

ğŸ“ íŒ¨í„´ë³„ ì˜ˆì‹œ (ìµœëŒ€ 3ê°œ):

  Baseline í¬í•¨ (change_from_baseline):
    - Baseline
    - Baseline
    - Baseline

  ê¸°ê°„ íŒ¨í„´ (í…ìŠ¤íŠ¸ ìˆ«ì+ë‹¨ìœ„):
    - eight weeks
    - within three months of study enrollment
    - within three months of study enrollment

  ê¸°ê°„ íŒ¨í„´ (Day/Month/Week N ë‹¨ë…):
    - Initial training (Day 0), Day 7, Day 14, Day 28, and Month 3
    - Initial training (Day 0), Day 7, Day 14, Day 28, and Month 3
    - week 26

  ê¸°ê°„ íŒ¨í„´ (ìˆ«ì+ë‹¨ìœ„):
    - 3 months
    - 12 months
    - 24 months

  ê¸°íƒ€/ë¶ˆëª…í™•:
    - during procedure
    - directly after intervention
    - directly after intervention

  ê¸°ê°„ íŒ¨í„´ (Up to):
    - CSF will be collected at Visit 1 (up to 30 days after the screening visit)
    - Up to 5 weeks
    - Up to 5 weeks

  ê¸°ê°„ íŒ¨í„´ (For N Months/Weeks/Days):
    - Daily for 90 days (the length of the diet intervention)
    - Every day for 28 days
    - At each office visit, for 96 months, until patient left the practice, or until d...

  ê¸°ê°„ íŒ¨í„´ (Through):
    - through study completion , an average of 1 year
    - through study completion , an average of 1 year
    - through study completion , an average of 2 years

  ê¸°ê°„ íŒ¨í„´ (Year N):
    - Year 1, Year 2-3
    - Year 1, Year 2-3
    - Year 1, Year 2-3

  ê¸°ê°„ íŒ¨í„´ (At Day/Week/Month N):
    - Prior to version 6 of the protocol, final assessments were performed at Week 42,...
    - Primary efficacy analysis at Week 28
    - Slopes will be estimated by using SIB data at Week 0, 5, 9, 13, 15, 20, 24, and ...

  ì‘ë‹µë¥ /ë¹„ìœ¨:
    - percentage

================================================================================
3. measure íŒ¨í„´ ë¶„ì„ (Outcome ë‹¨ìœ„)
================================================================================

ğŸ“ measure_raw ê¸¸ì´ í†µê³„:
  í‰ê· : 63.4ì
  ìµœì†Œ: 2ì
  ìµœëŒ€: 255ì

ğŸ”¤ ì•½ì–´ ì‚¬ìš© ë¶„ì„ (Outcome ë‹¨ìœ„):
  âœ… ê´„í˜¸ ì•ˆ ì•½ì–´ í¬í•¨: 5,739ê±´ (22.4%)
  âŒ ì•½ì–´ ì—†ìŒ: 19,854ê±´ (77.6%)

ğŸ† ìƒìœ„ 20ê°œ measure (ë¹ˆë„ìˆœ):
   1. [  48ê±´] Neuropsychiatric Inventory (NPI)
   2. [  28ê±´] Montreal Cognitive Assessment (MoCA)
   3. [  27ê±´] Mini-Mental State Examination (MMSE)
   4. [  20ê±´] Biological Parameters in blood
   5. [  20ê±´] Adverse Events
   6. [  20ê±´] Cognition
   7. [  20ê±´] Cognitive function
   8. [  18ê±´] Adverse events
   9. [  17ê±´] MMSE
  10. [  17ê±´] Caregiver Burden
  11. [  16ê±´] Neuropsychiatric Inventory
  12. [  14ê±´] Pharmacokinetics (PK) of J4 Dry Powder Capsule
  13. [  14ê±´] Depression
  14. [  13ê±´] Perceived Stress Scale
  15. [  13ê±´] Acceptability
  16. [  12ê±´] Zarit Burden Interview
  17. [  12ê±´] Geriatric Depression Scale
  18. [  12ê±´] Change From Baseline in Cognitive Measure
  19. [  12ê±´] Preliminary efficacy data (screening)
  20. [  11ê±´] Safety and tolerability

================================================================================
ğŸ“Š measure ì•½ì–´ ì¶”ì¶œ - Study ë‹¨ìœ„ ë¶„ì„
================================================================================

ğŸ“‹ ì „ì²´ Study ìˆ˜: 3,867ê±´
  â€¢ Primary outcome ìˆëŠ” Study: 3,867ê±´
  â€¢ Secondary outcome ìˆëŠ” Study: 2,906ê±´

âœ… ì•½ì–´ ì¶”ì¶œ ì„±ê³µë¥  (í•´ë‹¹ outcomeì´ ìˆëŠ” Study ê¸°ì¤€):
  ğŸ“Œ PRIMARY: 966ê±´ / 3,867ê±´ (25.0%)
     â†’ PRIMARY outcomeì´ ìˆëŠ” 3,867ê±´ ì¤‘ 966ê±´ì—ì„œ ì•½ì–´ ì¶”ì¶œ ì„±ê³µ
  ğŸ“Œ SECONDARY: 1,183ê±´ / 2,906ê±´ (40.7%)
     â†’ SECONDARY outcomeì´ ìˆëŠ” 2,906ê±´ ì¤‘ 1,183ê±´ì—ì„œ ì•½ì–´ ì¶”ì¶œ ì„±ê³µ

ğŸ¯ ìƒì„¸ ë¶„ë¥˜ (ì „ì²´ 3,867ê±´ Study ê¸°ì¤€):
  âœ… ë‘˜ ë‹¤ ì„±ê³µ: 507ê±´ (13.1%)
     â†’ PRIMARY ì•½ì–´ ì¶”ì¶œ ì„±ê³µ + SECONDARY ì•½ì–´ ì¶”ì¶œ ì„±ê³µ
  ğŸ“Œ PRIMARYë§Œ ì„±ê³µ: 459ê±´ (11.9%)
     â†’ PRIMARY ì•½ì–´ ì¶”ì¶œ ì„±ê³µ + SECONDARY ì•½ì–´ ì¶”ì¶œ ì‹¤íŒ¨
  ğŸ“Œ SECONDARYë§Œ ì„±ê³µ: 676ê±´ (17.5%)
     â†’ PRIMARY ì•½ì–´ ì¶”ì¶œ ì‹¤íŒ¨ + SECONDARY ì•½ì–´ ì¶”ì¶œ ì„±ê³µ
  âŒ ë‘˜ ë‹¤ ì‹¤íŒ¨: 2,225ê±´ (57.5%)
     â†’ PRIMARY ì•½ì–´ ì¶”ì¶œ ì‹¤íŒ¨ + SECONDARY ì•½ì–´ ì¶”ì¶œ ì‹¤íŒ¨

  â†’ ê²€ì¦: 507 + 459 + 676 + 2,225 = 3,867ê±´
  â†’ ê²€ì¦: PRIMARY ì„±ê³µ = 507 + 459 = 966ê±´ âœ“
  â†’ ê²€ì¦: SECONDARY ì„±ê³µ = 507 + 676 = 1,183ê±´ âœ“

================================================================================
ğŸ“Š timeFrame íŒŒì‹± - Study ë‹¨ìœ„ ë¶„ì„
================================================================================

ğŸ“‹ ì „ì²´ Study ìˆ˜: 3,867ê±´
  â€¢ PRIMARY outcome ìˆëŠ” Study: 3,867ê±´
  â€¢ SECONDARY outcome ìˆëŠ” Study: 2,906ê±´
  â€¢ PRIMARY outcomeì˜ measure ì•½ì–´ ì¶”ì¶œ ì„±ê³µ: 966ê±´
  â€¢ SECONDARY outcomeì˜ measure ì•½ì–´ ì¶”ì¶œ ì„±ê³µ: 1,183ê±´

âœ… PRIMARY Outcome (measure ì•½ì–´ ì¶”ì¶œ ì„±ê³µí•œ 966ê±´ ê¸°ì¤€):
  âœ… outcome + frame ë‘˜ ë‹¤ ì„±ê³µ: 821ê±´ (85.0%)
  ğŸ“Œ outcomeë§Œ ì„±ê³µ (frame ì‹¤íŒ¨): 145ê±´ (15.0%)
  ğŸ“Œ frameë§Œ ì„±ê³µ (measure ì‹¤íŒ¨, PRIMARY outcome ìˆìŒ): 2,257ê±´
  â†’ ê²€ì¦ (measure ì„±ê³µ ê¸°ì¤€): 966ê±´ = 966ê±´
  â†’ ê²€ì¦ (PRIMARY outcome ì „ì²´ ê¸°ì¤€): 3,223ê±´ â‰¤ 3,867ê±´

âœ… SECONDARY Outcome (measure ì•½ì–´ ì¶”ì¶œ ì„±ê³µí•œ 1,183ê±´ ê¸°ì¤€):
  âœ… outcome + frame ë‘˜ ë‹¤ ì„±ê³µ: 1,035ê±´ (87.5%)
  ğŸ“Œ outcomeë§Œ ì„±ê³µ (frame ì‹¤íŒ¨): 148ê±´ (12.5%)
  ğŸ“Œ frameë§Œ ì„±ê³µ (measure ì‹¤íŒ¨, SECONDARY outcome ìˆìŒ): 1,358ê±´
  â†’ ê²€ì¦ (measure ì„±ê³µ ê¸°ì¤€): 1,183ê±´ = 1,183ê±´
  â†’ ê²€ì¦ (SECONDARY outcome ì „ì²´ ê¸°ì¤€): 2,541ê±´ â‰¤ 2,906ê±´

================================================================================
4. description íŒ¨í„´ ë¶„ì„
================================================================================

ğŸ“Š 'change from baseline' íŒ¨í„´ ë¶„ì„:
  âœ… ë°œê²¬: 1,838ê±´ (8.5%)
  âŒ ë¯¸ë°œê²¬: 19,750ê±´ (91.5%)
  ğŸ“‹ ì „ì²´: 21,588ê±´

================================================================================
ğŸ”¬ íŒŒì‹± ë¶ˆê°€ëŠ¥ ì¼€ì´ìŠ¤ - ê¸°ê´€/ë‹´ë‹¹ìë³„ ì›ì¸ ë¶„ì„
================================================================================

[LEAD_SPONSORë³„ íŒŒì‹± ì‹¤íŒ¨ ì¼€ì´ìŠ¤]
ìˆœìœ„    ìŠ¤í°ì„œëª…                                     í´ë˜ìŠ¤             Total      Null       Unparseable     ì‹¤íŒ¨ìœ¨       
--------------------------------------------------------------------------------------------------------------
1     Avid Radiopharmaceuticals                INDUSTRY        126        0          41              32.5     %
2     University Hospital, Grenoble            OTHER           49         0          38              77.6     %
3     Institut National de la SantÃ© Et de la   OTHER_GOV       64         0          36              56.2     %
4     AstraZeneca                              INDUSTRY        143        0          35              24.5     %
5     Assistance Publique - HÃ´pitaux de Pari   OTHER           145        0          33              22.8     %
6     South China Center For Innovative Phar   OTHER           63         0          29              46.0     %
7     Phonak AG, Switzerland                   INDUSTRY        27         0          27              100.0    %
8     University Hospital, Tours               OTHER           71         0          23              32.4     %
9     University of Genova                     OTHER           34         0          22              64.7     %
10    Fondazione Don Carlo Gnocchi Onlus       OTHER           63         0          21              33.3     %
11    University Hospital, Bordeaux            OTHER           208        0          20              9.6      %
12    GlaxoSmithKline                          INDUSTRY        347        4          19              5.5      %
13    University of California, Los Angeles    OTHER           170        0          18              10.6     %
14    University of Paris 5 - Rene Descartes   OTHER           32         0          18              56.2     %
15    GE Healthcare                            INDUSTRY        38         7          16              51.6     %
16    Maastricht University Medical Center     OTHER           39         0          16              41.0     %
17    SK Chemicals Co., Ltd.                   INDUSTRY        16         0          16              100.0    %
18    Storz Medical AG                         INDUSTRY        58         0          15              25.9     %
19    Centre Hospitalier Universitaire de Ni   OTHER           89         0          15              16.9     %
20    Zhejiang Hospital                        OTHER           15         0          15              100.0    %

[íŒŒì‹± ì‹¤íŒ¨ ì¼€ì´ìŠ¤ ìƒ˜í”Œ]

ğŸ“Œ timeFrame íŒŒì‹± ì‹¤íŒ¨ ìƒ˜í”Œ (Top 20):
   1. [  34ê±´] At inclusion
   2. [  25ê±´] at inclusion
   3. [  24ê±´] 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
   4. [  21ê±´] at enrollment
   5. [  18ê±´] 30 minutes
   6. [  18ê±´] Approximately 10-15 minutes
   7. [  16ê±´] The 4th ã€8th and 12th week after taking Silkworm pupa powder.
   8. [  15ê±´] 5 minutes
   9. [  15ê±´] 05/01/2008-05/30/2020
  10. [  14ê±´] 50-60 min after injection
  11. [  13ê±´] 10 minutes
  12. [  13ê±´] 75 minutes
  13. [  13ê±´] once a year
  14. [  12ê±´] immediately post-treatment
  15. [  10ê±´] enrollment visit
  16. [  10ê±´] Screening
  17. [  10ê±´] End of study : around May 2022
  18. [  10ê±´] The 4th ã€8th and 12th week after taking placebo.
  19. [   9ê±´] acute (less than 60 minutes)
  20. [   9ê±´] once during the third week of the follow-up

ğŸ“Œ measure ì•½ì–´ ì¶”ì¶œ ì‹¤íŒ¨ ìƒ˜í”Œ (Top 20):
   1. [  20ê±´] Cognitive function
   2. [  20ê±´] Cognition
   3. [  20ê±´] Adverse Events
   4. [  20ê±´] Biological Parameters in blood
   5. [  18ê±´] Adverse events
   6. [  17ê±´] MMSE
   7. [  17ê±´] Caregiver Burden
   8. [  16ê±´] Neuropsychiatric Inventory
   9. [  14ê±´] Depression
  10. [  13ê±´] Perceived Stress Scale
  11. [  13ê±´] Acceptability
  12. [  12ê±´] Change From Baseline in Cognitive Measure
  13. [  12ê±´] Zarit Burden Interview
  14. [  12ê±´] Geriatric Depression Scale
  15. [  11ê±´] Safety and tolerability
  16. [  11ê±´] Efficacy
  17. [  11ê±´] ADAS-cog
  18. [  11ê±´] Blood pressure
  19. [  10ê±´] Weight
  20. [  10ê±´] Total ketones

--------------------------------------------------------------------------------
[OFFICIALë³„ íŒŒì‹± ì‹¤íŒ¨ ì¼€ì´ìŠ¤]
ìˆœìœ„    ë‹´ë‹¹ìëª…                           ì†Œì†                                  Total      Unparseable     ì‹¤íŒ¨ìœ¨       
--------------------------------------------------------------------------------------------------------------
1     Pfizer CT.gov Call Center      Pfizer                              646        147             22.9     %
2     Bristol-Myers Squibb           Bristol-Myers Squibb                283        125             44.5     %
3     GSK Clinical Trials            GlaxoSmithKline                     341        58              17.0     %
4     Roland Beisteiner, Prof.       Medical University of Vienna        42         42              100.0    %
5     Clinical Trials                Hoffmann-La Roche                   376        36              9.6      %
6     Richard Levy, MD, PhD          Institut National de la SantÃ© Et    45         36              80.0     %
7     Call 1-877-CTLILLY (1-877-28   Eli Lilly and Company               326        27              8.4      %
8     Kathleen Pichora-Fuller, Pro   University of Toronto               27         27              100.0    %
9     Chief Medical Officer          Avid Radiopharmaceuticals           55         25              45.5     %
10    Sophie Portrat                 Laboratoire de Psychologie et Neu   23         23              100.0    %
11    Benoit Lemaire                 Laboratoire de Psychologie et Neu   23         23              100.0    %
12    Nicola L Bragazzi, MD, PhD,    Universita degli Studi di Genova    22         22              100.0    %
13    Ramani S Moonesinghe, MBBS,    University College, London          21         20              95.2     %
14    Victoire LEROY, MD             CHRU de Tours                       18         18              100.0    %
15    Sophie SB Blanchet, Ph.D       University of Paris                 32         18              56.2     %

================================================================================
5. LEAD_SPONSORë³„ ë¶„ì„
================================================================================

ğŸ¢ Top 20 LEAD_SPONSOR (Studies ê¸°ì¤€):
ìˆœìœ„    ìŠ¤í°ì„œëª…                                     í´ë˜ìŠ¤             Studies    Outcomes   Parseable    Parse%    
--------------------------------------------------------------------------------------------------------------
1     Pfizer                                   INDUSTRY        62         640        303          47.6     %
2     Eli Lilly and Company                    INDUSTRY        49         484        213          44.9     %
3     Avid Radiopharmaceuticals                INDUSTRY        42         126        62           49.2     %
4     Indiana University                       OTHER           34         236        228          96.6     %
5     Massachusetts General Hospital           OTHER           32         204        137          67.2     %
6     Johns Hopkins University                 OTHER           31         189        197          104.2    %
7     Wyeth is now a wholly owned subsidiary   INDUSTRY        31         74         43           76.8     %
8     Merck Sharp & Dohme LLC                  INDUSTRY        30         207        183          88.4     %
9     GlaxoSmithKline                          INDUSTRY        30         347        95           27.7     %
10    Centre Hospitalier Universitaire de Ni   OTHER           30         89         45           50.6     %
11    Chang Gung Memorial Hospital             OTHER           29         148        74           50.0     %
12    Washington University School of Medici   OTHER           27         189        90           47.6     %
13    AstraZeneca                              INDUSTRY        26         143        54           37.8     %
14    University of Washington                 OTHER           26         136        99           73.9     %
15    Brigham and Women's Hospital             OTHER           25         77         79           102.6    %
16    Assistance Publique - HÃ´pitaux de Pari   OTHER           25         145        110          75.9     %
17    Emory University                         OTHER           25         254        149          60.6     %
18    Hoffmann-La Roche                        INDUSTRY        25         317        161          50.8     %
19    Eisai Inc.                               INDUSTRY        23         199        107          54.6     %
20    NYU Langone Health                       OTHER           23         187        95           50.8     %

--------------------------------------------------------------------------------
LEAD_SPONSORë³„ timeFrame íŒ¨í„´ (Top 10)
--------------------------------------------------------------------------------

  ğŸ“Œ Pfizer (ì´ 640ê±´):
     â€¢ Period pattern: 229ê±´ (35.8%)
     â€¢ Year pattern: 0ê±´ (0.0%)
     â€¢ Up to pattern: 39ê±´ (6.1%)
     â€¢ Through pattern: 0ê±´ (0.0%)
     â€¢ Null/Empty: 3ê±´ (0.5%)
     â†’ âœ… íŒŒì‹± ê°€ëŠ¥: 268ê±´ (41.9%)
     â†’ âŒ íŒŒì‹± ì–´ë ¤ì›€: 369ê±´ (57.7%)

  ğŸ“Œ Eli Lilly and Company (ì´ 484ê±´):
     â€¢ Period pattern: 127ê±´ (26.2%)
     â€¢ Year pattern: 6ê±´ (1.2%)
     â€¢ Up to pattern: 45ê±´ (9.3%)
     â€¢ Through pattern: 4ê±´ (0.8%)
     â€¢ Null/Empty: 10ê±´ (2.1%)
     â†’ âœ… íŒŒì‹± ê°€ëŠ¥: 182ê±´ (37.6%)
     â†’ âŒ íŒŒì‹± ì–´ë ¤ì›€: 292ê±´ (60.3%)

  ğŸ“Œ GlaxoSmithKline (ì´ 347ê±´):
     â€¢ Period pattern: 35ê±´ (10.1%)
     â€¢ Year pattern: 0ê±´ (0.0%)
     â€¢ Up to pattern: 38ê±´ (11.0%)
     â€¢ Through pattern: 0ê±´ (0.0%)
     â€¢ Null/Empty: 4ê±´ (1.2%)
     â†’ âœ… íŒŒì‹± ê°€ëŠ¥: 73ê±´ (21.0%)
     â†’ âŒ íŒŒì‹± ì–´ë ¤ì›€: 270ê±´ (77.8%)

  ğŸ“Œ Hoffmann-La Roche (ì´ 317ê±´):
     â€¢ Period pattern: 30ê±´ (9.5%)
     â€¢ Year pattern: 0ê±´ (0.0%)
     â€¢ Up to pattern: 66ê±´ (20.8%)
     â€¢ Through pattern: 0ê±´ (0.0%)
     â€¢ Null/Empty: 0ê±´ (0.0%)
     â†’ âœ… íŒŒì‹± ê°€ëŠ¥: 96ê±´ (30.3%)
     â†’ âŒ íŒŒì‹± ì–´ë ¤ì›€: 221ê±´ (69.7%)

  ğŸ“Œ Emory University (ì´ 254ê±´):
     â€¢ Period pattern: 117ê±´ (46.1%)
     â€¢ Year pattern: 2ê±´ (0.8%)
     â€¢ Up to pattern: 15ê±´ (5.9%)
     â€¢ Through pattern: 0ê±´ (0.0%)
     â€¢ Null/Empty: 8ê±´ (3.1%)
     â†’ âœ… íŒŒì‹± ê°€ëŠ¥: 134ê±´ (52.8%)
     â†’ âŒ íŒŒì‹± ì–´ë ¤ì›€: 112ê±´ (44.1%)

  ğŸ“Œ Indiana University (ì´ 236ê±´):
     â€¢ Period pattern: 156ê±´ (66.1%)
     â€¢ Year pattern: 0ê±´ (0.0%)
     â€¢ Up to pattern: 23ê±´ (9.7%)
     â€¢ Through pattern: 13ê±´ (5.5%)
     â€¢ Null/Empty: 0ê±´ (0.0%)
     â†’ âœ… íŒŒì‹± ê°€ëŠ¥: 192ê±´ (81.4%)
     â†’ âŒ íŒŒì‹± ì–´ë ¤ì›€: 44ê±´ (18.6%)

  ğŸ“Œ University Hospital, Bordeaux (ì´ 208ê±´):
     â€¢ Period pattern: 150ê±´ (72.1%)
     â€¢ Year pattern: 0ê±´ (0.0%)
     â€¢ Up to pattern: 5ê±´ (2.4%)
     â€¢ Through pattern: 0ê±´ (0.0%)
     â€¢ Null/Empty: 0ê±´ (0.0%)
     â†’ âœ… íŒŒì‹± ê°€ëŠ¥: 155ê±´ (74.5%)
     â†’ âŒ íŒŒì‹± ì–´ë ¤ì›€: 53ê±´ (25.5%)

  ğŸ“Œ Xuanwu Hospital, Beijing (ì´ 207ê±´):
     â€¢ Period pattern: 117ê±´ (56.5%)
     â€¢ Year pattern: 27ê±´ (13.0%)
     â€¢ Up to pattern: 49ê±´ (23.7%)
     â€¢ Through pattern: 1ê±´ (0.5%)
     â€¢ Null/Empty: 0ê±´ (0.0%)
     â†’ âœ… íŒŒì‹± ê°€ëŠ¥: 194ê±´ (93.7%)
     â†’ âŒ íŒŒì‹± ì–´ë ¤ì›€: 13ê±´ (6.3%)

  ğŸ“Œ Merck Sharp & Dohme LLC (ì´ 207ê±´):
     â€¢ Period pattern: 111ê±´ (53.6%)
     â€¢ Year pattern: 0ê±´ (0.0%)
     â€¢ Up to pattern: 37ê±´ (17.9%)
     â€¢ Through pattern: 0ê±´ (0.0%)
     â€¢ Null/Empty: 0ê±´ (0.0%)
     â†’ âœ… íŒŒì‹± ê°€ëŠ¥: 148ê±´ (71.5%)
     â†’ âŒ íŒŒì‹± ì–´ë ¤ì›€: 59ê±´ (28.5%)

  ğŸ“Œ Massachusetts General Hospital (ì´ 204ê±´):
     â€¢ Period pattern: 99ê±´ (48.5%)
     â€¢ Year pattern: 0ê±´ (0.0%)
     â€¢ Up to pattern: 18ê±´ (8.8%)
     â€¢ Through pattern: 1ê±´ (0.5%)
     â€¢ Null/Empty: 0ê±´ (0.0%)
     â†’ âœ… íŒŒì‹± ê°€ëŠ¥: 118ê±´ (57.8%)
     â†’ âŒ íŒŒì‹± ì–´ë ¤ì›€: 86ê±´ (42.2%)

================================================================================
6. OFFICIAL(ë‹´ë‹¹ì)ë³„ ë¶„ì„
================================================================================

ğŸ‘¤ Top 20 OFFICIAL (Studies ê¸°ì¤€):
ìˆœìœ„    ë‹´ë‹¹ìëª…                                ì†Œì†                                       Studies    Outcomes   Parseable    Parse%    
-----------------------------------------------------------------------------------------------------------------------------
1     Pfizer CT.gov Call Center           Pfizer                                   64         646        318          49.5     %
2     Call 1-877-CTLILLY (1-877-285-455   Eli Lilly and Company                    35         326        115          35.8     %
3     Clinical Trials                     Hoffmann-La Roche                        30         376        179          47.6     %
4     Bristol-Myers Squibb                Bristol-Myers Squibb                     27         283        47           16.7     %
5     GSK Clinical Trials                 GlaxoSmithKline                          27         341        93           27.3     %
6     Medical Monitor                     Wyeth is now a wholly owned subsidiary   26         42         21           87.5     %
7     Chief Medical Officer               Avid Radiopharmaceuticals                22         55         33           60.0     %
8     Novartis Pharmaceuticals            Novartis Pharmaceuticals                 20         129        37           28.7     %
9     Medical Director                    Merck Sharp & Dohme LLC                  19         174        154          88.5     %
10    Janssen Research & Development, L   Janssen Research & Development, LLC      16         128        109          85.2     %
11    Madhav Thambisetty, MD, PhD         National Institute on Aging (NIA)        14         21         23           109.5    %
12    Medical Director                    Biogen                                   13         106        59           55.7     %
13    Johnson & Johnson Pharmaceutical    Johnson & Johnson Pharmaceutical Resea   12         24         0            0.0      %
14    Danna Jennings, MD                  Institute for Neurodegenerative Disord   12         21         18           90.0     %
15    Email contact via H. Lundbeck A/S   LundbeckClinicalTrials@lundbeck.com      11         64         4            6.2      %
16    Tammie Benzinger, MD, PhD           Washington University School of Medici   10         27         27           100.0    %
17    Chief Medical Officer               Avid Radiopharmaceuticals, Inc.          9          25         8            32.0     %
18    Suzanne Craft, PhD                  Wake Forest University Health Sciences   9          42         15           35.7     %
19    Mariana Figueiro, PhD               Icahn School of Medicine at Mount Sina   7          68         10           14.7     %
20    Call 1-877-CTLILLY (1-877-285-455   Eli Lilly and Company                    7          60         21           35.0     %

--------------------------------------------------------------------------------
OFFICIALë³„ measure íŒ¨í„´ (Top 10)
--------------------------------------------------------------------------------

  ğŸ“Œ Pfizer CT.gov Call Center (Pfizer) - ì´ 646ê±´:
     â€¢ ì•½ì–´ í¬í•¨: 202ê±´ (31.3%)
     â€¢ Change from baseline: 48ê±´ (7.4%)

  ğŸ“Œ Clinical Trials (Hoffmann-La Roche) - ì´ 376ê±´:
     â€¢ ì•½ì–´ í¬í•¨: 147ê±´ (39.1%)
     â€¢ Change from baseline: 78ê±´ (20.7%)

  ğŸ“Œ GSK Clinical Trials (GlaxoSmithKline) - ì´ 341ê±´:
     â€¢ ì•½ì–´ í¬í•¨: 109ê±´ (32.0%)
     â€¢ Change from baseline: 171ê±´ (50.1%)

  ğŸ“Œ Call 1-877-CTLILLY (1-877-285-4559) or 1 (Eli Lilly and Company) - ì´ 326ê±´:
     â€¢ ì•½ì–´ í¬í•¨: 145ê±´ (44.5%)
     â€¢ Change from baseline: 50ê±´ (15.3%)

  ğŸ“Œ Bristol-Myers Squibb (Bristol-Myers Squibb) - ì´ 283ê±´:
     â€¢ ì•½ì–´ í¬í•¨: 100ê±´ (35.3%)
     â€¢ Change from baseline: 23ê±´ (8.1%)

  ğŸ“Œ Medical Director (Merck Sharp & Dohme LLC) - ì´ 174ê±´:
     â€¢ ì•½ì–´ í¬í•¨: 62ê±´ (35.6%)
     â€¢ Change from baseline: 44ê±´ (25.3%)

  ğŸ“Œ Novartis Pharmaceuticals (Novartis Pharmaceuticals) - ì´ 129ê±´:
     â€¢ ì•½ì–´ í¬í•¨: 57ê±´ (44.2%)
     â€¢ Change from baseline: 25ê±´ (19.4%)

  ğŸ“Œ Janssen Research & Development, LLC Clin (Janssen Research & Development, LLC) - ì´ 128ê±´:
     â€¢ ì•½ì–´ í¬í•¨: 38ê±´ (29.7%)
     â€¢ Change from baseline: 6ê±´ (4.7%)

  ğŸ“Œ Medical Director (Biogen) - ì´ 106ê±´:
     â€¢ ì•½ì–´ í¬í•¨: 38ê±´ (35.8%)
     â€¢ Change from baseline: 20ê±´ (18.9%)

  ğŸ“Œ Dimitrios I Kapogiannis, M.D. (National Institute on Aging (NIA)) - ì´ 104ê±´:
     â€¢ ì•½ì–´ í¬í•¨: 70ê±´ (67.3%)
     â€¢ Change from baseline: 0ê±´ (0.0%)

================================================================================
7. Sponsor Classë³„ íŒ¨í„´ ë¶„ì„
================================================================================

ğŸ“Š Sponsor Classë³„ í†µê³„:
Class                Studies      Outcomes     Period Pattern                 Abbrev                         Avg Length  
------------------------------------------------------------------------------------------------------------------------
OTHER                2449         15859        9,184ê±´(57.9%) 3,027ê±´(19.1%) 54.4       
INDUSTRY             1275         8917         2,353ê±´(26.4%) 2,536ê±´(28.4%) 80.3       
OTHER_GOV            68           471          285ê±´(60.5%) 61ê±´(13.0%) 51.9       
FED                  36           147          117ê±´(79.6%) 29ê±´(19.7%) 48.4       
NIH                  27           162          34ê±´(21.0%) 80ê±´(49.4%) 61.2       
NETWORK              11           34           20ê±´(58.8%) 5ê±´(14.7%) 64.0       
INDIV                1            3            3ê±´(100.0%) 1ê±´(33.3%) 50.3       

================================================================================
8. ê¸°ê´€/ë‹´ë‹¹ìë³„ ì˜ˆìƒ ë§¤í•‘ ì‹¤íŒ¨ìœ¨ ë¶„ì„
================================================================================

[LEAD_SPONSORë³„ - ì˜ˆìƒ timeFrame íŒŒì‹± ì‹¤íŒ¨ìœ¨]
ìŠ¤í°ì„œëª…                                               Total      Null       Complex    Failure Rate
----------------------------------------------------------------------------------------------------
GemVax & Kael                                      22         0          22         100.0      %
G2GBio, Inc.                                       24         0          24         100.0      %
Shahid Sadoughi University of Medical Sciences a   28         0          28         100.0      %
REGEnLIFE SAS                                      31         0          31         100.0      %
University of California, Santa Barbara            23         0          23         100.0      %
Technical University of Madrid                     32         0          32         100.0      %
Phonak AG, Switzerland                             27         0          27         100.0      %
Hopeful Aging                                      56         0          56         100.0      %
Hope Biosciences LLC                               49         0          49         100.0      %
Uskudar University                                 36         0          36         100.0      %

================================================================================
ğŸ“Š ì¢…í•© ë¦¬í¬íŠ¸
================================================================================

ğŸ“Š ê¸°ë³¸ í†µê³„:
  ì´ Studies: 3,867ê±´
  ì´ Outcomes: 25,593ê±´
  Studyë‹¹ í‰ê·  Outcomes: 6.6ê°œ
  PRIMARY: 9,514ê±´ (37.2%)
  SECONDARY: 16,079ê±´ (62.8%)

================================================================================
âœ… ì§„ë‹¨ ì™„ë£Œ!
================================================================================

```
